Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses. J Med Virol 2021 Apr;93(4):1843-1846

Date

12/15/2020

Pubmed ID

33314219

Pubmed Central ID

PMC8159020

DOI

10.1002/jmv.26728

Scopus ID

2-s2.0-85097604434 (requires institutional sign-in at Scopus site)   32 Citations

Abstract

In this commentary, we shed light on the role of the mammalian target of rapamycin (mTOR) pathway in viral infections. The mTOR pathway has been demonstrated to be modulated in numerous RNA viruses. Frequently, inhibiting mTOR results in suppression of virus growth and replication. Recent evidence points towards modulation of mTOR in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We discuss the current literature on mTOR in SARS-CoV-2 and highlight evidence in support of a role for mTOR inhibitors in the treatment of coronavirus disease 2019.

Author List

Karam BS, Morris RS, Bramante CT, Puskarich M, Zolfaghari EJ, Lotfi-Emran S, Ingraham NE, Charles A, Odde DJ, Tignanelli CJ

Author

Rachel S. Morris MD Assistant Professor in the Surgery department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Animals
Antiviral Agents
Humans
Middle East Respiratory Syndrome Coronavirus
RNA Viruses
Signal Transduction
TOR Serine-Threonine Kinases
Virus Replication